
Margaret Hamburg, M.D.
Co-president, InterAcademy Partnership
NTI board member Margaret A. Hamburg, MD, is joining NTI’s leadership to serve as interim vice president of the NTI | bio program in February. Hamburg, an internationally recognized leader in public health and medicine, replaces Beth Cameron, PhD, who has moved to the White House to rebuild the National Security Council’s Office of Global Health Security and Biodefense and advance the Biden Administration’s agenda on global health security.
Hamburg’s relationship with NTI goes back to its launch in 2001, when she was named as the organization’s founding senior scientist and biological program vice president. She went on to become commissioner of the Food and Drug Administration and foreign secretary of the National Academy of Medicine.
Hamburg joined NTI’s Board of Directors in 2017.
Sign up for our newsletter to get the latest on nuclear and biological threats.
More than 35 leading experts highlight the risks posed by rapidly advancing capabilities at the convergence of AI and the life sciences and call on governments, industry, the scientific community, and funders to take action to safeguard this technology.
A growing coalition of funders is stepping up to ensure that scientific innovation doesn’t come at the cost of safety and security. Representatives from influential, non-governmental funding organizations who advance critical life science research around the world met virtually on May 9, 2025 for the second Bio Funders Forum.
Executive Order 14292 on “Improving the Safety and Security of Biological Research" suggests some promising actions toward protecting modern bioscience and biotechnology against misuse. However, the order threatens to undermine U.S. capabilities to protect the American public from biological threats by requiring a pause in gain-of-function research.
Sign up for regular updates on innovative, real-world solutions to existential threats.
{ location = 'https://www.nti.org/get-updates/' }, 300);">Get Updates